Acumen Pharmaceuticals (ABOS) AI Stock Analysis

• Market Cap: $104.79M
• Dividend Yield: N/A
• Average Volume (3M): 415.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.26
• Revenue Growth: N/A
• EPS Growth: -60.99%
• Country: US
• Employees: 61
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.44
• Shares Outstanding: 60,573,425
• 10 Day Avg. Volume: 506,634
• 30 Day Avg. Volume: 415,590
• PEG Ratio: -0.02
• Price to Book (P/B): 0.57
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.20
• Enterprise Value/Market Cap: -0.41
• Enterprise Value/Revenue: -241.59
• Enterprise Value/Gross Profit: -483.18
• Enterprise Value/Ebitda: 0.33
• 1Y Price Target: $5.67
• Price Target Upside: 227.75% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 36 Underperform
• Price Target: ―

Acumen Pharmaceuticals has significant financial challenges with no revenue and increasing losses, heavily impacting its stock score. The completion of a key clinical trial phase is a positive, but technical indicators show bearish sentiment. Valuation metrics are unfavorable with ongoing losses. While cash reserves provide short-term financial stability, the company's financial health and market sentiment necessitate significant improvements to achieve a higher stock score.

Positive Factors

Clinical Trial Progress

Successfully completing enrollment for the ALTITUDE AD Phase 2 study ahead of schedule demonstrates strong execution and potential for advancing Alzheimer's treatment, which is critical for long-term growth and market positioning.

Financial Stability

A robust cash position expected to fund operations into 2027 provides financial stability, allowing the company to focus on R&D without immediate pressure for external financing.

Subcutaneous Formulation Development

Positive results from the subcutaneous formulation study enhance treatment flexibility and patient accessibility, potentially broadening market reach and improving competitive positioning.

Negative Factors

No Revenue Generation

The absence of revenue generation poses significant challenges in achieving profitability and sustaining operations long-term without continued external funding.

Increasing Operational Losses

Rising operational losses highlight financial strain and the need for successful clinical outcomes and partnerships to achieve future profitability.

High Injection Site Reactions

While reactions were mild, the high rate of injection site reactions could impact patient compliance and the overall perception of the treatment's safety profile.

Acumen Pharmaceuticals Business Overview & Revenue Model

Company Description

Acumen Pharmaceuticals, Inc. (ABOS) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for the treatment of neurodegenerative diseases, with an emphasis on Alzheimer's disease. The company's lead product candidate is ACU193, a monoclonal antibody that selectively targets toxic amyloid-beta oligomers, which are believed to play a key role in the pathogenesis of Alzheimer's disease. Acumen Pharmaceuticals is engaged in advancing its clinical trials and research to address unmet medical needs in the neurodegenerative disease sector.

How the Company Makes Money

Acumen Pharmaceuticals generates revenue primarily through funding from investors, partnerships, and collaborations rather than traditional product sales, as it is still in the clinical trial phase. The company relies on strategic alliances with pharmaceutical companies, research institutions, and government grants to support its research and development activities. Additionally, Acumen may receive milestone payments and royalties from potential future licensing agreements for its drug candidates, contingent upon successful clinical development and regulatory approval.

Acumen Pharmaceuticals Financial Statement Overview

Summary

Acumen Pharmaceuticals faces significant financial challenges with no revenue generation and mounting losses. The balance sheet is stable with no debt, but declining assets could pose future liquidity risks. Cash flow issues are prominent, with heavy reliance on financing activities to support operations. Strategic measures are required to address revenue generation and improve cash flow sustainability.

Income Statement

Acumen Pharmaceuticals' income statement shows a persistent lack of revenue generation, with total revenues standing at zero for the past four years. The company has been experiencing substantial net losses, with a notable increase in net loss from $73.2 million in 2020 to $102.3 million in 2024. The absence of revenue combined with increasing operating losses highlights significant challenges in achieving profitability.

Balance Sheet

The balance sheet reflects a stable equity base, with stockholders' equity exceeding liabilities, indicating a low risk of insolvency. However, the company has seen a decline in total assets from $310.1 million in 2023 to $239 million in 2024. The absence of debt provides financial flexibility, but the consistent decrease in asset base may indicate potential liquidity concerns.

Cash Flow

The cash flow statement reveals negative free cash flow over the years, with an increasing deficit from $43 million in 2023 to $86 million in 2024. Operating cash flow remains negative, highlighting ongoing challenges in generating cash from operations. Financing activities have been a critical source of cash, but reliance on external financing may not be sustainable long-term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	178.00K	0.00	0.00	0.00	0.00	1.44M
Gross Profit	89.00K	0.00	0.00	-169.00K	-12.30M	-6.56M
EBITDA	-129.04M	-98.08M	-51.61M	-42.69M	-19.58M	-7.91M
Net Income	-133.35M	-102.33M	-52.37M	-42.86M	-100.61M	-7.33M
Balance Sheet
Total Assets	142.22M	238.99M	310.13M	196.59M	230.33M	44.43M
Cash, Cash Equivalents and Short-Term Investments	126.61M	171.56M	243.52M	177.60M	194.24M	43.78M
Total Debt	3.60M	29.70M	28.49M	105.00K	0.00	0.00
Total Liabilities	49.05M	57.18M	43.15M	7.81M	5.15M	63.02M
Stockholders Equity	93.17M	181.82M	266.97M	188.78M	225.18M	-18.59M
Cash Flow
Free Cash Flow	-123.75M	-86.23M	-43.09M	-35.31M	-18.00M	-7.45M
Operating Cash Flow	-123.66M	-86.22M	-43.06M	-35.15M	-17.96M	-7.45M
Investing Cash Flow	137.35M	48.03M	-171.67M	39.19M	-104.12M	0.00
Financing Cash Flow	-45.00K	6.93M	151.75M	3.91M	200.47M	44.67M

Acumen Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.73
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABOS, the sentiment is Neutral. The current price of 1.73 is below the 20-day moving average (MA) of 2.04, below the 50-day MA of 1.80, and above the 200-day MA of 1.38, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 40.07 is Neutral, neither overbought nor oversold. The STOCH value of 18.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ABOS.

Acumen Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VTGN	54 Neutral	$124.87M	―	―	―	-33.00%	54.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADVM	49 Neutral	$94.71M	-0.50	-417.79%	―	-100.00%	-42.12%
IKT	46 Neutral	$118.48M	-1.46	-97.49%	―	-100.00%	62.82%
SRZN	43 Neutral	$107.90M	-0.90	―	―	-63.96%	-28.50%
TCRX	40 Neutral	$62.42M	-0.98	-76.44%	―	-10.03%	11.06%
ABOS	36 Underperform	$104.79M	-0.78	-85.93%	―	―	-60.99%

Acumen Pharmaceuticals Corporate Events

Acumen Pharmaceuticals Completes Enrollment for Phase 2 Study

On March 27, 2025, Acumen Pharmaceuticals announced the completion of enrollment for its ALTITUDE-AD Phase 2 study, investigating sabirnetug for early Alzheimer’s disease, with topline results expected in late 2026. The company reported a cash balance of $231.5 million as of December 31, 2024, projected to support operations into the first half of 2027, despite a net loss of $102.3 million for 2024 due to increased R&D expenses.